{"product_id":"clpt-bcg-matrix","title":"(CLPT) ClearPoint Neuro, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis ClearPoint Neuro, Inc. BCG Matrix helps you see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. The page already shows a real preview of the analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClearPoint Neuro Navigation System\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClearPoint Neuro Navigation System is the clearest Star in ClearPoint Neuro, Inc.'s BCG Matrix: it is the core platform for MRI-guided, minimally invasive brain surgery, used inside the MRI suite for precise targeting and placement. It drives the company's growth story because it sits at the center of recurring procedural use and expanding clinical adoption.\u003c\/p\u003e\n\u003cp\u003eAs the main growth engine, it benefits from a high-value neuro navigation market where accuracy and real-time imaging matter most. Its strength is simple: it helps surgeons place therapies more precisely, and that keeps it central to ClearPoint Neuro, Inc.'s long-term revenue mix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDeep Brain Stimulation electrode placement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClearPoint Neuro’s MRI-guided platform supports deep brain stimulation electrode placement with sub-millimeter targeting, which is critical for functional neurosurgery. DBS is still a core use case because it treats Parkinson’s disease, essential tremor, and dystonia, and the addressable patient pool keeps growing as diagnosis and referral rates rise. That supports premium adoption in a niche with durable clinical value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrain biopsy needle placement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClearPoint Neuro, Inc.'s brain biopsy needle placement supports targeting for intracranial lesions, and MRI guidance helps improve precision in a high-value procedure. This fits a growth-led Star profile because it sits in a specialized, clinically important niche where accuracy drives adoption and reimbursement value. The category benefits from rising demand for image-guided neurosurgery, even as ClearPoint Neuro continues to scale its broader platform.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eIntracranial drug delivery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClearPoint Neuro’s intracranial drug delivery supports controlled infusion directly into the brain, so it sits in a high-innovation niche with meaningful clinical upside. The company has said this platform is built for precision placement, and the market is still early, which fits a Star profile in the BCG Matrix. Adoption is building, but the use case is specialized and could expand as more neurosurgical programs adopt it.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh innovation, early adoption\u003c\/li\u003e\n\u003cli\u003eDirect brain delivery, precision focused\u003c\/li\u003e\n\u003cli\u003eStar profile if growth keeps building\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLaser catheter guidance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLaser catheter guidance is a niche \"Star\" for ClearPoint Neuro because it fits minimally invasive brain procedures and can support higher-use workflows in neuro-oncology and epilepsy. The addressable need is large: epilepsy affects about 50 million people worldwide, and brain cancers remain a major surgical target, so guided laser therapy has real runway if adoption keeps rising.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFits minimally invasive brain therapy\u003c\/li\u003e\n\u003cli\u003eSupports neuro-oncology and epilepsy use\u003c\/li\u003e\n\u003cli\u003eTaps large, unmet clinical demand\u003c\/li\u003e\n\u003cli\u003eHigh growth, likely early-stage scale\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClearPoint Neuro’s MRI-Guided Star Growth Engine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eClearPoint Neuro, Inc.'s Stars are its MRI-guided brain navigation and therapy tools, led by the ClearPoint Neuro Navigation System. These products fit a Star role because they combine high growth with strong clinical need in DBS, biopsy, and intracranial drug delivery.\u003c\/p\u003e\n\u003cp\u003eEpilepsy affects about 50 million people worldwide, so laser-guided and minimally invasive brain procedures still have room to scale. The same is true for precise MRI-guided targeting, which keeps adoption tied to real surgical demand.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClearPoint Neuro Navigation System\u003c\/td\u003e\n\u003ctd\u003eCore growth platform\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDBS and biopsy guidance\u003c\/td\u003e\n\u003ctd\u003ePrecision drives adoption\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntracranial drug delivery\u003c\/td\u003e\n\u003ctd\u003eEarly but high-upside use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eClearPoint Neuro BCG Matrix maps its portfolio across Stars, Cash Cows, Question Marks, and Dogs to guide invest, hold, or divest decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOne-page ClearPoint Neuro, Inc. BCG Matrix for quick quadrant insights and easier strategic decisions\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a traceable source trail for ClearPoint Neuro, Inc., strengthening credibility and making decisions easier to defend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDisposable procedure kits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDisposable procedure kits are ClearPoint Neuro, Inc.'s classic Cash Cow: they recur with every case, so each installed system can keep generating follow-on sales. That repeat use means steadier revenue and less sales friction than capital equipment, which fits a mature, high-margin BCG layer. In practice, the installed base keeps pulling kit demand case after case.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInstalled U.S. system base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClearPoint Neuro’s U.S. installed base is a Cash Cow because the company is still mainly U.S.-focused, so each new system can feed recurring service and support revenue after the sale. Mature installed accounts are cheaper to keep than to win, which supports higher-margin repeat revenue. That makes the base a stable source of cash even if new placements slow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eService and training contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClearPoint Neuro, Inc. uses service and training contracts as a cash cow because its MRI-suite workflow needs clinical support, onboarding, and repeat training after adoption. In the latest reported year, ClearPoint Neuro, Inc. generated about $35 million of revenue, and these post-sale services help turn installed systems into recurring cash. Once hospitals are trained, support demand stays steady, so the revenue is sticky and low cost to defend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eProcedure accessories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProcedure accessories are a cash-cow line for ClearPoint Neuro, Inc.: DBS, biopsy, and infusion cases need repeat-purchase consumables, so revenue tracks procedure volume more than platform growth. The company’s latest filings still show this stream is driven by installed-site utilization, not one-time system sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRepeat buys\u003c\/li\u003e\n\u003cli\u003eLinked to DBS, biopsy, infusion\u003c\/li\u003e\n\u003cli\u003eLower growth, steady volume\u003c\/li\u003e\n\u003cli\u003eValue rises with installed sites\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNavigation software upkeep\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNavigation software upkeep fits ClearPoint Neuro, Inc.'s Cash Cow profile because software and maintenance fees repeat after adoption, while the clinical workflow is already proven. That makes growth steadier than the launch phase and helps support recurring cash flow, even if the platform is not a high-growth engine.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRecurring maintenance revenue\u003c\/li\u003e\n\u003cli\u003eEstablished clinical use case\u003c\/li\u003e\n\u003cli\u003eSteadier post-launch growth\u003c\/li\u003e\n\u003cli\u003eSupports ongoing cash flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClearPoint Neuro’s Steady Cash Engine: Repeat Revenue Streams\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eClearPoint Neuro, Inc.'s Cash Cows are its repeat-use revenue streams: disposable kits, accessories, service, training, and software upkeep. In the latest reported year, revenue was about $35 million, and these post-sale lines stay tied to the installed base, so they keep cash coming in with less selling effort. That makes them steadier than new-system sales.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCash cow line\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eKits, accessories, service\u003c\/td\u003e\n\u003ctd\u003eRepeat use\u003c\/td\u003e\n\u003ctd\u003e~$35M revenue\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eClearPoint Neuro, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact ClearPoint Neuro, Inc. BCG Matrix document you’ll receive after purchase. No sample pages, no watermarks, and no demo content—just the full, ready-to-use file. Once purchased, it’s instantly available for download and use. What you see here is what you get.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy MRI Interventions branding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegacy MRI Interventions branding is a legacy asset in ClearPoint Neuro, Inc.'s BCG view, not a growth driver. ClearPoint Neuro rebranded from MRI Interventions, Inc. in February 2020, so the old name no longer supports strategy or sales. The brand adds no current growth role; it mainly reflects pre-2020 history, while ClearPoint Neuro now sells under one identity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-core capital equipment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClearPoint Neuro, Inc. stays tightly focused on MRI-guided brain surgery tools, so non-core capital equipment fits the Dogs bucket. Low-volume gear outside that niche has weak scale and can soak up cash, inventory, and support time without clear growth. In fiscal 2025, that kind of business is still a small, low-return use of capital versus the core platform.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOne-off custom integration work\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOne-off custom integration work is a Dogs item for ClearPoint Neuro, Inc. because each project is highly tailored, hard to repeat, and slow to scale versus the core platform. That low repeatability makes margins and backlog less predictable, so it is weaker than recurring device and software revenue. It can support customer wins, but it should not drive the BCG view.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePeripheral accessories with low differentiation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClearPoint Neuro, Inc.’s peripheral accessories fit Dog territory when they lack clear clinical edge and face price pressure. In FY2025, the company’s revenue base was still driven by core navigation and therapy uses, so low-volume accessories likely added little share or growth. That makes them hard to defend when buyers can switch on price.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow differentiation = pricing pressure\u003c\/li\u003e\n\u003cli\u003eSmall volume = weak growth impact\u003c\/li\u003e\n\u003cli\u003eLimited share gain = Dog profile\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSmall non-U.S. commercialization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClearPoint Neuro, Inc. remains mainly a U.S. business, so non-U.S. commercialization is still a small part of the mix. That limited reach means overseas sales have not yet become a scale driver, which fits a low-share, low-growth Dogs profile. International expansion may add optionality, but it is not the core demand engine today.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eU.S.-centric revenue base\u003c\/li\u003e\n\u003cli\u003eSmall overseas footprint\u003c\/li\u003e\n\u003cli\u003eLow share outside the U.S.\u003c\/li\u003e\n\u003cli\u003eNot a scale market yet\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClearPoint Neuro's Dogs: Legacy Gear, Low-Scale Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs in ClearPoint Neuro, Inc.'s BCG view are mostly legacy or low-volume items: the MRI Interventions name was retired in February 2020, and non-core gear still lacks scale. In FY2025, the core business stayed centered on MRI-guided brain surgery, so custom work, accessories, and limited non-U.S. sales added little growth.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eDog signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy brand\u003c\/td\u003e\n\u003ctd\u003eRebranded Feb 2020\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-core gear\u003c\/td\u003e\n\u003ctd\u003eLow scale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCell and gene therapy delivery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCell and gene therapy delivery is a high-growth adjacency for ClearPoint Neuro, but it is still a small part of the revenue mix. The company’s delivery tools can help enable future therapies, yet current market share is early, so the segment fits a Question Mark in the BCG Matrix. It needs more capital and commercial wins to turn 2025 investment into a future Star.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBoston Scientific partnership programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClearPoint Neuro, Inc. lists Boston Scientific as a strategic partner, and that partnership could reach larger hospital and device channels. But demand ownership is not public, so the program’s current share and profit pool are unclear; that makes it a Question Mark.\u003c\/p\u003e\n\u003cp\u003eBoston Scientific is a large-scale partner, with 2025 revenue above $16 billion, so even small pull-through can matter. Still, until ClearPoint shows partner-led program revenue, conversion, and repeat use, the upside is promising but unproven.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBlackrock Neurotech collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBlackrock Neurotech sits in ClearPoint Neuro, Inc.’s question-mark bucket: it is a named partner, and the neurotech market is growing fast, but commercial share is still early.\u003c\/p\u003e\n\u003cp\u003eThe upside is real, yet ClearPoint has not shown dominant share or scale from this collaboration in 2025 results, so it needs more adoption before it can move to a star.\u003c\/p\u003e\n\u003cp\u003eFor BCG terms, this is a high-potential, low-share play where execution and clinic uptake will decide whether value grows or stalls.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePhilips MRI-suite integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClearPoint Neuro, Inc.’s Philips MRI-suite integration can widen the guided-therapy workflow, since Philips posted €18.2 billion in 2024 sales and a global MRI base that supports cross-sell. ClearPoint still needs broader hospital adoption to prove it can turn that access into durable market share. Until use scales, this looks more like a Question Mark than a cash generator.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExpands workflow reach\u003c\/li\u003e\n\u003cli\u003eLeverages Philips MRI footprint\u003c\/li\u003e\n\u003cli\u003eAdoption still unproven\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eUCSF and Johns Hopkins translational programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClearPoint Neuro, Inc.'s ties with University of California, San Francisco and Johns Hopkins University fit Question Marks in the BCG Matrix: the science is strong, but near-term revenue is still limited and not separately disclosed. These translational programs can seed future products, but they need clinical proof, regulatory wins, and adoption before they become material.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh potential, low current revenue\u003c\/li\u003e\n\u003cli\u003eEarly-stage academic-to-commercial path\u003c\/li\u003e\n\u003cli\u003eFuture upside depends on trials\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClearPoint Neuro’s Big Upside, But 2025 Proof Is Still Limited\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eClearPoint Neuro’s question marks are early, high-upside adjacencies: cell and gene therapy delivery, partner-led workflows, and academic collaborations. They can scale, but 2025 revenue impact is still small and share is not proven. Boston Scientific topped $16B in 2025 revenue, and Philips posted €18.2B in 2024 sales, so channel reach exists; conversion still needs proof.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCell and gene therapy\u003c\/td\u003e\n\u003ctd\u003eLow share, high growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBoston Scientific\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$16B 2025 revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhilips\u003c\/td\u003e\n\u003ctd\u003e€18.2B 2024 sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234240864521,"sku":"clpt-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/clpt-bcg-matrix.webp?v=1785715103","url":"https:\/\/dcfanalyst.com\/products\/clpt-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}